The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

21 Dec 2015 07:00

RNS Number : 6572J
Fastnet Equity PLC
21 December 2015
 

21 December 2015

 

Fastnet Equity plc

("Fastnet" or the "Company")

Interim Results for the six months ended 30 September 2015

 

We are pleased to report on the progress of Fastnet Equity plc ("Fastnet" or the "Company") and present the unaudited interim results for the six month period ended 30 September 2015.

 

Operational Highlights

· Concluded detailed asset review of the Company's oil and gas portfolio in light of the rapidly deteriorating economic conditions in the oil and gas sector during the last year

· Transition from an Oil & Gas business to an investment company following the adoption of an investing policy to acquire companies or businesses in the healthcare sector which was approved by shareholders on 28 August 2015

· Post period end, the oil and gas subsidiaries were demerged into a separate company, Fastnet Hydrocarbons Limited, on 17 December 2015. Fastnet Hydrocarbons Limited is held in trust for the benefit of shareholders on the register of the Company as at the close of business on 16 December 2015

· Fastnet will no longer have any ongoing interest or further cost exposure in respect of oil and gas assets

 

Financial and Corporate Highlights

· US$15.5m cash balance at 30 September 2015 (US$16.8m at 31 March 2015, US$18.8m at 30 September 2014)

· Net loss for the period of US$1.5m (6 months to 31 March 2015: loss of US$39.7m, 6 months to 30 September 2014: loss of US$1.6m). The current period net loss comprises general and administrative costs of US$1.2m and exploration and evaluation costs expensed of US$0.3m

· Change of the functional currency of Company to Euros (€) with the cash balance of US$15.1m converted into €13.7m on 31 October 2015 at an FX rate of US$1:€0.905

· Cash balance of €13.6m as at 30 November 2015 prior to the grant of an unsecured 4 year term loan €660,000 to finance residual running of oil and gas assets

Cathal Friel, Non-Executive Chairman, commented:

 

"Following the recently announced demerger of our oil and gas assets the Company is well positioned to focus on identifying and assessing potential investment targets within the healthcare sector." 

 

 

For further information please contact:

Fastnet Equity plc

+353 (1) 644 0007

Cathal Friel, Non-Executive Chairman

 

 

 

Shore Capital

+44 (0) 20 7408 4090

(Nomad & Joint Broker)

 

Bidhi Bhoma, Edward Mansfield

 

 

 

 

 

Davy

+353 (1) 679 6363

(ESM Adviser & Joint Broker)

 

John Frain, Anthony Farrell

 

 

 

Camarco

+44 (0) 20 3757 4980

Billy Clegg / Zoe Moulton

 

 

 

 

 

Consolidated Statement of Comprehensive Income

For the six months ended 30 September 2015

 

 

Unaudited

Audited

Audited

 

 

6 months to

 30 September 2015

6 months to

 30 September 2014

12 months to 31 March

 2015

 

Note

US$'000

US$'000

US$'000

Continuing operations

 

 

 

 

Revenue

 

-

-

-

Operational costs

 

-

-

-

Gross loss

 

-

-

-

General and administrative costs

 

(1,177)

(1,651)

(3,196)

Impairment of exploration and evaluation assets

 

(308)

-

(36,593)

Other operating expenses

 

(4)

-

(12)

Share based payments

 

(30)

(74)

(129)

Operating loss

 

(1,519)

(1,725)

(39,930)

Finance income

 

50

95

185

Net foreign exchange gain

 

10

2

4

Loss on ordinary activities before taxation

 

(1,459)

(1,628)

(39,741)

Tax on loss on ordinary activities

 

-

-

-

Loss and total comprehensive loss for the period attributable to the equity holders of the Company

 

(1,459)

(1,628)

(39,741)

 

Loss per share:

 

 

 

 

 

Loss per share - basic and diluted, attributable to ordinary equity holders of the parent (cent)

 

3

 

(0.42)

 

-(0.47)

 

(11.51)

 

 

 

 

Consolidated Statement of Financial Position

As at 30 September 2015

 

Unaudited

30 September 2015

Unaudited

30 September 2014

Audited

31 March

 2015

 

US$'000

US$'000

US$'000

Assets

 

 

 

Non-current assets

 

 

 

Property, plant and equipment

5

11

8

Exploration and evaluation assets

-

35,986

-

Total non-current assets

5

35,997

8

 

 

 

 

Current assets

 

 

 

Trade and other receivables

58

148

173

Cash and cash equivalents

15,516

18,827

16,790

Total current assets

15,574

18,975

16,963

Total assets

15,579

54,972

16,971

 

 

 

 

Equity and liabilities

 

 

 

Equity attributable to owners of the parent

 

 

 

Share capital

20,261

20,261

20,261

Share premium

38,918

38,918

38,918

Other reserves

2,110

1,996

2,080

Retained deficit

(46,251)

(6,679)

(44,792)

Total equity

15,038

54,496

16,467

 

 

 

 

Non-current liabilities

 

 

 

Liability for share based payments

-

2

-

Total non-current liabilities

-

2

-

 

 

 

 

Current liabilities

 

 

 

Trade and other payables

541

474

504

Total current liabilities

541

474

504

Total liabilities

541

476

504

Total equity and liabilities

15,579

54,972

16,971

 

 

 

Consolidated Statement of Cash Flows

For the six months ended 30 September 2015

 

Unaudited

Unaudited

Audited

 

6 months to

30 September 2015

6 months to

30 September 2014

12 months to 31 March

 2015

 

US$'000

US$'000

US$'000

Cash flows from operating activities

 

 

 

Group operating loss for the period

(1,519)

(1,725)

(39,930)

Depreciation

3

3

6

Share based payment expense

30

74

129

Impairment of exploration and evaluation assets

308

-

36,593

Movements in working capital and other adjustments:

 

 

 

Decrease/(increase) in trade and other receivables

115

(72)

(97)

Increase/(decrease) in trade and other payables

37

(393)

(496)

Net cash flow used in operating activities

(1,026)

(2,113)

(3,795)

 

 

 

 

Cash flow from investing activities

 

 

 

Payments for property, plant and equipment

-

(1)

-

Expenditure on exploration and evaluation assets

(308)

(16,994)

(17,442)

Farm-in proceeds

-

20,410

20,410

Finance income

50

95

185

Net cash flow (used in)/from investing activities

(258)

3,510

3,153

 

 

 

 

Cash flow from financing activities

 

 

 

Net proceeds from issue of equity instruments

-

-

-

Net cash flow from financing activities

-

-

-

 

 

 

 

Exchange and other movements

10

2

4

 

 

 

 

Net change in cash and cash equivalents

(1,274)

1,399

(638)

Cash and cash equivalents at beginning of period

16,790

17,428

17,428

Cash and cash equivalents at end of period

15,516

18,827

16,790

 

 

Consolidated Statement of Changes in Equity
 

 

 

 

 

 

Share

capital

 

 

 

Share premium

 

 

Share based payment reserve

 

 

 

Merger reserve

 

Reverse asset acquisition reserve

 

 

 

Capital reserve

 

 

 

Retained deficit

 

 

 

 

Total

 

US$'000

US$'000

US$'000

US$'000

US$'000

US$'000

US$'000

US$'000

Balance at 1 April 2014

20,261

38,918

1,584

11,478

(11,256)

9

(5,051)

55,943

Loss and total comprehensive loss for the period

-

-

-

-

-

-

(1,628)

(1,628)

Share based payments

-

-

181

-

-

-

-

181

Balance at 30 September 2014 (Unaudited)

20,261

38,918

1,765

11,478

(11,256)

9

(6,679)

54,496

 

 

 

 

 

 

 

 

 

Balance at 1 October 2014

20,261

38,918

1,765

11,478

(11,256)

9

(6,679)

54,496

Loss and total comprehensive loss for the period

-

-

-

-

-

-

(38,113)

(38,113)

Share based payments

-

-

84

-

-

-

-

84

Balance at 31 March 2015

(Audited)

20,261

38,918

1,849

11,478

(11,256)

9

(44,792)

16,467

 

 

 

 

 

 

 

 

 

Balance at 1 April 2015

20,261

38,918

1,849

11,478

(11,256)

9

(44,792)

16,467

Loss and total comprehensive loss for the period

-

-

-

-

-

-

(1,459)

(1,459)

Share based payments

-

-

30

-

-

-

-

30

Balance at 30 September 2015 (Unaudited)

20,261

38,918

1,879

11,478

(11,256)

9

(46,251)

15,038

 

Company Information

 

1. General Information

Fastnet Equity plc ("Fastnet" or the "Company") is a company incorporated in England and Wales. Details of the registered office, the officers and advisers to the Company are presented on the Company Information page at the end of this report. The Company is listed on the AIM market of the London Stock Exchange (ticker: FAST) and the Enterprise Securities Market of the Irish Stock Exchange (ticker: FOI).

 

The principal activity of the Company during the period was oil and gas exploration. At a general meeting of the Company on 28 August 2015, a fundamental change of business and adoption of an Investing Policy was approved by the shareholders of the Company. The Investing Policy is to acquire companies or businesses in the healthcare sector particularly those in the biopharma sector.

 

The interim results of the Company for the six month period ended 30 September 2015 comprise the Company and its subsidiaries (together the "Group").

 

2. Basis of Preparation

The interim results have been prepared on the basis of the recognition and measurement requirements of International Financial Reporting Standards ("IFRS") as adopted by the European Union ("EU"), and their interpretations adopted by the International Accounting Standards Board ("IASB"). As is permitted by the AIM rules the Directors have not adopted the requirements of IAS34 "Interim Financial Reporting" in preparing the financial statements. Accordingly the financial statements are not in full compliance with IFRS and have neither been audited nor reviewed pursuant to guidance issued by the Auditing Practises Board. The accounting policies used in the preparation of the interim financial information are the same as those used in the Company's audited financial statements for the year ended 31 March 2015 and are expected to be used in the 31 March 2016 year-end financial statements.

 

The financial information for the six months ended 30 September 2014 and 30 September 2015 is unaudited. The financial information presented for the year ended 31 March 2015 is an extraction from the Group's audited accounts and therefore does not constitute statutory accounts within the meaning of Section 434 of the Companies Act 2006 on which the auditors issued an unqualified report. The auditor's report also did not contain a statement under Section 498(2) or 498 (3) of the Companies Act 2006 and did not include reference to any matters the auditor drew attention by way of emphasis. The accounts for the year ended 31 March 2015 have been delivered to the Registrar of Companies. The Directors consider that the financial information presented in this Interim Report represents fairly the financial position, operations and cash flows for the period, in conformity with IFRS. The Interim Report for the six months ended 30 September 2015 was approved by the Directors on 21 December 2015.

 

Presentation of Balances

The Financial Statements are presented in US Dollars ("US$") which was the functional and presentational currency of the Company during the period and the functional currency of all the Group's subsidiary companies. Balances in the Financial Statements are rounded to the nearest thousand ("US$'000") except where otherwise indicated. In light of the Company's fundamental change in business the directors have reviewed the functional currency of Company and determined with effect from 1 November 2015 that Euro ("") will be the appropriate functional currency going forwards (see note 4.)

 

3. Loss per Share - Basic and Diluted

The Group presents basic and diluted loss per share ("LPS") data for its Ordinary Shares. Basic LPS is calculated by dividing the loss attributable to Ordinary Shareholders of the Company by the weighted average number of Ordinary Shares outstanding during the period. Diluted LPS is determined by adjusting the loss attributable to Ordinary Shareholders and the weighted average number of Ordinary Shares outstanding for the effects of all dilutive potential Ordinary Shares, which comprise warrants and share options granted by the Company.

 

The calculation of loss per share is based on the following:

 

6 months to 30 September 2015

6 months to 30 September 2014

12 months to 31 March 2015

Loss after tax attributable to equity holders of the parent (US$'000)

(1,459)

(1,628)

(39,741)

Weighted average number of Ordinary Shares in issue

345,369,071

345,369,071

345,369,071

Fully diluted average number of Ordinary Shares in issue

345,369,071

345,369,071

345,369,071

Basic and diluted loss per share (cent)

(0.42)

(0.47)

(11.51)

 

Where a loss has occurred, basic and diluted LPS are the same because the outstanding share options and warrants are anti-dilutive. Accordingly, diluted LPS equals the basic LPS.

 

The share options and warrants outstanding as at 30 September 2015 totalled 13,819,726 (31 March 2015: 20,397,423, 30 September 2014: 25,397,423) and are potentially dilutive.

 

4. Subsequent Events

Change of Functional and Presentational Currency

Following the companies fundamental change in business in August 2015 the Company will be funded in Pounds Sterling ("£"), alongside incurring costs in £, Euro ("€") and US$. Having considered the aggregate effect of all relevant factors, the Directors have concluded that € will be the appropriate functional currency of the Company with the change becoming effective from 1 November 2015. This reflects the fact that € is the predominant currency in the economic environment in which the Company operates and expects to operate in going forward. In line with IAS 21 when there is a change in an entity's functional currency the change should take place with effect from the date the Company determined that the characteristics required to identify the functional currency had changed. The Company determined that this change occurred during Q4 2015 and is effective for accounting purposes from 1 November 2015. The Group and Company will also adopt the € as the presentational currency going forward.

 

Demerger of Oil and Gas Assets

The Company's oil and gas subsidiaries were acquired by Fastnet Hydrocarbons Limited ("Fastnet Hydrocarbons"), on 17 December 2015 for an aggregate sum of £1. Fastnet Hydrocarbons is held in trust for the benefit of shareholders on the register of the Company as at the close of business on 16 December 2015. As a consequence the Group will no longer have any ongoing interest or further cost exposure in respect of oil and gas assets.

 

Prior to the demerger, as at 30 November 2015, the Company's cash balances amounted to €13.6m. As part of the demerger an unsecured four year term loan of €660,000 was granted to finance the residual running of oil and gas assets.

 

5. Copy of the Interim Report

Copies of the Interim Report are available to download from the Company's website at

www.fastnetequity.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR FEFESSFISELE
Date   Source Headline
6th Jan 20225:30 pmRNSAmryt Pharma
6th Jan 20227:00 amGNWKey Dates for AIM Delisting
4th Jan 202212:00 pmGNWThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
4th Jan 20227:00 amGNWTotal Voting Rights
1st Dec 20217:00 amGNWTotal Voting Rights
30th Nov 20217:00 amGNWDirector/PDMR Shareholding
23rd Nov 202112:00 pmGNWAmryt Provides Update on Regulatory Review Process for Oleogel-S10
22nd Nov 20217:00 amGNWAmryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM
3rd Nov 202111:00 amGNWAmryt Reports Strong Q3 2021 Results
1st Nov 20211:00 pmGNWTotal Voting Rights
1st Nov 20217:00 amRNSAmryt Supports Acromegaly Awareness Day
22nd Oct 20217:00 amRNSAmryt Supports Global EB Awareness Week 2021
20th Oct 202112:00 pmGNWAmryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3
19th Oct 202112:00 pmGNWAmryt Announces New Patents for Oleogel-S10 and Mycapssa®
23rd Sep 202112:00 pmRNSAmryt Supports Global FH Awareness Day
13th Sep 202112:00 pmGNWAmryt Raises Full Year 2021 Revenue Guidance to $220M - $225M
1st Sep 20217:00 amGNWTotal Voting Rights
19th Aug 20217:00 amGNWAmryt Issues Ordinary Shares and Total Voting Rights
13th Aug 20211:23 pmRNSHolding(s) in Company - Replacement
11th Aug 202111:30 amRNSHoldings in Company
11th Aug 202110:36 amRNSHolding(s) in Company
10th Aug 20212:20 pmGNWDirector/PDMR Shareholding
10th Aug 20219:53 amRNSHolding(s) in Company
9th Aug 202112:00 pmGNWAmryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
6th Aug 202112:00 pmGNWAmryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
5th Aug 20213:50 pmGNWAmryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
28th Jul 20213:00 pmGNWResult of General Meetings
12th Jul 202112:00 pmGNWAmryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6
28th Jun 202112:00 pmGNWPublication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
15th Jun 202111:45 amGNWAmryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
7th Jun 202112:00 pmGNWFDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
3rd Jun 20217:00 amGNWFDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
2nd Jun 20211:30 pmGNWAmryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
5th May 20214:41 pmRNSSecond Price Monitoring Extn
5th May 20214:35 pmRNSPrice Monitoring Extension
5th May 202112:05 pmGNWAmryt Reports Record Q1 2021 Financial and Operating Results
5th May 202112:00 pmGNWAmryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
15th Apr 202112:00 pmGNWAmryt to Report Q1 2021 Results and Host Conference Call & Webcast on May 5
6th Apr 20217:00 amGNWAmryt Announces the Appointment of Sheila Frame as President Americas
31st Mar 202111:00 amRNSAmryt Supports World Lipodystrophy Day
31st Mar 20217:00 amGNWAmryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
30th Mar 20217:00 amGNWAmryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS
29th Mar 20217:00 amGNWAmryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)
23rd Mar 20217:00 amGNWAmryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
22nd Mar 20217:00 amGNWAmryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)
15th Mar 202110:00 amGNWDirector/PDMR Shareholding
12th Mar 20217:00 amGNWExercise of Options and Total Voting Rights
11th Mar 202111:30 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
8th Mar 20216:00 pmGNWDirector/PDMR Shareholding
8th Mar 20217:00 amGNWAmryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.